HUE047140T2 - Apixaban formulációk - Google Patents

Apixaban formulációk

Info

Publication number
HUE047140T2
HUE047140T2 HUE17178613A HUE17178613A HUE047140T2 HU E047140 T2 HUE047140 T2 HU E047140T2 HU E17178613 A HUE17178613 A HU E17178613A HU E17178613 A HUE17178613 A HU E17178613A HU E047140 T2 HUE047140 T2 HU E047140T2
Authority
HU
Hungary
Prior art keywords
apixaban formulations
apixaban
formulations
Prior art date
Application number
HUE17178613A
Other languages
English (en)
Hungarian (hu)
Inventor
Jatin Patel
Charles Frost
Jingpin Jia
Chandra Vema-Varapu
Original Assignee
Bristol Myers Squibb Holdings Ireland
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE047140(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland, Pfizer filed Critical Bristol Myers Squibb Holdings Ireland
Publication of HUE047140T2 publication Critical patent/HUE047140T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE17178613A 2010-02-25 2011-02-24 Apixaban formulációk HUE047140T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30805610P 2010-02-25 2010-02-25

Publications (1)

Publication Number Publication Date
HUE047140T2 true HUE047140T2 (hu) 2020-04-28

Family

ID=43901603

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE17178613A HUE047140T2 (hu) 2010-02-25 2011-02-24 Apixaban formulációk
HUE15190823A HUE043932T2 (hu) 2010-02-25 2011-02-24 Apixaban formulációk
HUE11707284A HUE027168T2 (en) 2010-02-25 2011-02-24 Apixaban formulations
HUE17175788A HUE047139T2 (hu) 2010-02-25 2011-02-24 Apixaban formulációk

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE15190823A HUE043932T2 (hu) 2010-02-25 2011-02-24 Apixaban formulációk
HUE11707284A HUE027168T2 (en) 2010-02-25 2011-02-24 Apixaban formulations
HUE17175788A HUE047139T2 (hu) 2010-02-25 2011-02-24 Apixaban formulációk

Country Status (31)

Country Link
US (5) US9326945B2 (enExample)
EP (7) EP3246021B1 (enExample)
JP (4) JP5846647B2 (enExample)
KR (4) KR20170126016A (enExample)
CN (3) CN109602716A (enExample)
AU (1) AU2011220775B2 (enExample)
BR (1) BR112012021337A8 (enExample)
CA (1) CA2791171C (enExample)
CO (1) CO6640207A2 (enExample)
CY (5) CY1117434T1 (enExample)
DK (5) DK3257500T3 (enExample)
ES (5) ES2757603T3 (enExample)
HK (2) HK1243947B (enExample)
HR (5) HRP20160179T1 (enExample)
HU (4) HUE047140T2 (enExample)
IL (3) IL309564A (enExample)
IN (1) IN2012DN06587A (enExample)
LT (4) LT3257500T (enExample)
MX (3) MX2012009244A (enExample)
NZ (1) NZ601738A (enExample)
PE (3) PE20130378A1 (enExample)
PL (5) PL3246021T3 (enExample)
PT (5) PT3246021T (enExample)
RS (5) RS59810B1 (enExample)
RU (1) RU2685724C2 (enExample)
SG (2) SG182750A1 (enExample)
SI (5) SI3257500T1 (enExample)
SM (5) SMT201900212T1 (enExample)
TR (1) TR201903195T4 (enExample)
WO (1) WO2011106478A2 (enExample)
ZA (1) ZA201205807B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109602716A (zh) 2010-02-25 2019-04-12 百时美-施贵宝爱尔兰控股无限责任公司 包含药物组合物的片剂或胶囊剂
WO2013164839A2 (en) * 2012-03-06 2013-11-07 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
WO2013174498A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
WO2014052678A1 (en) * 2012-09-26 2014-04-03 Bristol-Myers Squibb Company Apixaban liquid formulations
CN102908324A (zh) * 2012-10-31 2013-02-06 南京正科制药有限公司 一种阿哌沙班片
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
WO2014203275A2 (en) * 2013-06-18 2014-12-24 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
CA2954840A1 (en) 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CN104316637B (zh) * 2014-10-30 2016-08-17 江苏宝众宝达药业有限公司 高效液相色谱法测定阿哌沙班清洗残留量
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
WO2016181276A1 (en) * 2015-05-08 2016-11-17 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106913528A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 阿哌沙班微丸及其制备方法
WO2017121340A1 (zh) * 2016-01-12 2017-07-20 广东东阳光药业有限公司 阿哌沙班固体组合物及其制备方法
EP3195860A1 (de) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Verfahren zur herstellung eines apixaban-granulates
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (zh) * 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 一种阿哌沙班片及其制备方法
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
TN2019000063A1 (en) * 2016-09-24 2020-07-15 Kbp Biosciences Co Ltd Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
CN106420651B (zh) * 2016-09-28 2019-03-08 乐普药业股份有限公司 一种阿哌沙班片的制备方法
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
JP7044115B2 (ja) 2017-11-27 2022-03-30 三菱ケミカル株式会社 ゴム含有グラフト重合体組成物を含む熱可塑性樹脂の樹脂改質用組成物、ゴム含有グラフト重合体含有樹脂組成物およびその成形体
KR20190075566A (ko) 2017-12-21 2019-07-01 전자부품연구원 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법
TR201722523A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
ES2988919T3 (es) 2018-04-16 2024-11-22 Bristol Myers Squibb Co Formulaciones de apixaban
KR20190130411A (ko) * 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
JP2021535094A (ja) 2018-08-14 2021-12-16 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. 注射可能な医薬組成物およびその調製方法
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN111377915B (zh) * 2018-12-30 2023-10-24 鲁南制药集团股份有限公司 一种吡唑并-吡啶酮化合物晶型d
CN109464415B (zh) * 2019-01-09 2021-08-17 常州恒邦药业有限公司 阿哌沙班药物组合物及其制备方法
MA55568A (fr) 2019-11-13 2022-02-09 Unison Pharmaceuticals Pvt Ltd Compositions pharmaceutiques orodispersibles d'apixaban
CN111214442B (zh) * 2020-02-13 2021-12-10 山东百诺医药股份有限公司 一种阿哌沙班共微粉化物
CN111494326A (zh) * 2020-04-11 2020-08-07 南京正大天晴制药有限公司 一种阿哌沙班片及其制备方法
WO2022115051A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Direct compression method for non-micronised apixaban formulations
WO2022115052A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Improved wet granulation processes for apixaban comprising formulations
WO2022150030A2 (en) 2021-01-08 2022-07-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet of apixaban
TR202100250A2 (tr) 2021-01-08 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren fi̇lm kapli tablet
JP2022112698A (ja) * 2021-01-22 2022-08-03 東和薬品株式会社 アピキサバン含有医薬組成物
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
IL309098A (en) * 2021-06-08 2024-02-01 Taho Pharmaceuticals Ltd Apixaban layer product and its uses
EP4412586A1 (en) 2021-10-27 2024-08-14 Pharma-Data S.A. Apixaban suspension and preparation method
JP2024057549A (ja) * 2022-10-12 2024-04-24 日本ジェネリック株式会社 アピキサバンを含有する錠剤
KR102760108B1 (ko) 2024-04-09 2025-01-24 에바바이오 주식회사 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
ES2232202T3 (es) 1998-12-23 2005-05-16 Bristol-Myers Squibb Pharma Company Heterobiciclos que contienen nitrogeno como inhibidores del factor xa.
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
HRP20080382A2 (en) 2001-09-21 2008-12-31 Bristol-Myers Squibb Company A Delaware (Usa) Corporation LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
WO2004084943A1 (en) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US7434502B2 (en) 2004-07-21 2008-10-14 Husqvarna Outdoor Products Inc. Bar knob with cam-operated locking mechanism
US20060016084A1 (en) * 2004-07-24 2006-01-26 Ching-Lin Liao Laser-Based datum instrument
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
EP1951197A4 (en) 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
EP2061439A1 (en) * 2006-09-12 2009-05-27 Glaxo Group Limited Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
EP2586439A1 (en) * 2007-05-02 2013-05-01 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet ADP receptor inhibitor
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009135946A1 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
KR20110043655A (ko) 2008-07-11 2011-04-27 바스프 에스이 모폴로지 변경제로서의 양친매성 단백질
US20100018486A1 (en) * 2008-07-22 2010-01-28 Hung-Tao Liu Cathode energy fuel-saving device
EP4008327A1 (en) * 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
CN109602716A (zh) * 2010-02-25 2019-04-12 百时美-施贵宝爱尔兰控股无限责任公司 包含药物组合物的片剂或胶囊剂
WO2011110930A2 (en) * 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension

Also Published As

Publication number Publication date
CN102770126A (zh) 2012-11-07
DK3017811T3 (en) 2019-04-01
RU2012140690A (ru) 2014-03-27
US20160243101A1 (en) 2016-08-25
US20170202825A1 (en) 2017-07-20
PL3017811T3 (pl) 2019-06-28
LT3017811T (lt) 2019-02-25
JP2017039768A (ja) 2017-02-23
CO6640207A2 (es) 2013-03-22
US9326945B2 (en) 2016-05-03
CA2791171C (en) 2017-08-29
SI3251660T1 (sl) 2019-12-31
HRP20190430T8 (hr) 2019-06-14
DK3246021T3 (da) 2020-02-03
US20130045245A1 (en) 2013-02-21
RS59576B1 (sr) 2019-12-31
HK1243947B (en) 2020-06-19
SMT201900650T1 (it) 2020-01-14
RS59810B1 (sr) 2020-02-28
ES2758031T8 (es) 2020-08-05
JP2013521226A (ja) 2013-06-10
RU2685724C2 (ru) 2019-04-23
BR112012021337A8 (pt) 2016-11-29
EP3246021B1 (en) 2019-11-13
SMT201900212T1 (it) 2019-05-10
JP2016065086A (ja) 2016-04-28
ES2767848T3 (es) 2020-06-18
HRP20160179T1 (hr) 2016-04-08
PT3246021T (pt) 2020-02-21
IL251991A0 (en) 2017-06-29
PE20160042A1 (es) 2016-01-28
HUE043932T2 (hu) 2019-09-30
EP2538925B1 (en) 2015-12-16
KR20130009753A (ko) 2013-01-23
RS59593B1 (sr) 2020-01-31
ZA201205807B (en) 2016-01-27
PT3251660T (pt) 2019-12-02
MX353145B (es) 2017-12-20
KR20210124532A (ko) 2021-10-14
CY1122382T1 (el) 2021-01-27
CY1121597T1 (el) 2020-05-29
KR20170126016A (ko) 2017-11-15
TR201903195T4 (tr) 2019-03-21
SI3017811T1 (sl) 2019-04-30
HRP20200046T1 (hr) 2020-03-20
ES2758031T3 (es) 2020-05-04
HUE027168T2 (en) 2016-10-28
CY1117434T1 (el) 2017-04-26
IL221064A0 (en) 2012-09-24
DK3257500T3 (da) 2019-11-25
CN109602713A (zh) 2019-04-12
EP2538925A2 (en) 2013-01-02
HK1224216A1 (en) 2017-08-18
HK1243945B (en) 2020-06-19
PL3257500T3 (pl) 2020-03-31
WO2011106478A3 (en) 2012-04-12
EP3251660B1 (en) 2019-10-16
SI3257500T1 (sl) 2019-12-31
AU2011220775B2 (en) 2015-09-24
SMT201900649T1 (it) 2020-01-14
PE20130378A1 (es) 2013-03-30
SMT201600049B (it) 2016-04-29
PL3246021T3 (pl) 2020-04-30
LT3257500T (lt) 2019-12-10
HK1180248A1 (zh) 2013-10-18
SI3246021T1 (sl) 2020-03-31
MX2012009244A (es) 2012-08-23
PE20210468A1 (es) 2021-03-08
SI2538925T1 (sl) 2016-04-29
SMT202000034T1 (it) 2020-03-13
KR20230149861A (ko) 2023-10-27
EP3246021A1 (en) 2017-11-22
JP2017226679A (ja) 2017-12-28
SG10201501349VA (en) 2015-04-29
IL309564A (en) 2024-02-01
AU2011220775A1 (en) 2012-09-13
JP5846647B2 (ja) 2016-01-20
PL3251660T3 (pl) 2020-02-28
CY1122529T1 (el) 2021-01-27
ES2562279T3 (es) 2016-03-03
EP3257500A1 (en) 2017-12-20
HRP20192069T1 (hr) 2020-02-07
HUE047139T2 (hu) 2020-04-28
BR112012021337A2 (pt) 2016-10-25
JP6577980B2 (ja) 2019-09-18
IN2012DN06587A (enExample) 2015-10-23
DK2538925T3 (en) 2016-03-14
HRP20192064T1 (hr) 2020-02-21
PT3017811T (pt) 2019-03-21
CN109602716A (zh) 2019-04-12
EP3257500B1 (en) 2019-10-16
CA2791171A1 (en) 2011-09-01
HK1243946A1 (en) 2018-07-27
PT3257500T (pt) 2019-11-26
NZ601738A (en) 2014-02-28
JP6033945B2 (ja) 2016-11-30
EP3643301A1 (en) 2020-04-29
RS58699B1 (sr) 2019-06-28
RS54559B1 (sr) 2016-06-30
LT3246021T (lt) 2020-02-10
US20170202824A1 (en) 2017-07-20
MX364938B (es) 2019-05-15
EP3017811B1 (en) 2018-12-05
ES2714363T3 (es) 2019-05-28
JP6192078B2 (ja) 2017-09-06
KR101796300B1 (ko) 2017-11-10
WO2011106478A2 (en) 2011-09-01
ES2757603T3 (es) 2020-04-29
SG182750A1 (en) 2012-08-30
PL2538925T3 (pl) 2016-06-30
EP3662899A1 (en) 2020-06-10
HRP20190430T1 (hr) 2019-05-17
DK3251660T3 (da) 2019-11-25
CY1122384T1 (el) 2021-01-27
EP3017811A1 (en) 2016-05-11
PT2538925E (pt) 2016-03-18
US20200375968A1 (en) 2020-12-03
LT3251660T (lt) 2019-12-10
EP3251660A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
SMT201600049B (it) Formulazioni di apixaban
DK2648809T3 (da) Naturlige formuleringer
DK2640893T4 (da) Sammensætninger
GT201200303A (es) Formulaciones farmacéuticas
EP2552212A4 (en) IMPROVED FORMULATION
EP2531023A4 (en) IMPROVED FORMULATION
EP2628769A4 (en) FILM FORMING COMPOSITION
BR112012022294A2 (pt) articulador
DK2672817T3 (da) Forbedrede insekticide formuleringer
BR112013000109A2 (pt) composições
FI9608U1 (fi) Formulaatiot
DK2598472T3 (da) Formuleringer